First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours

Isabella Silins(Uppsala University), Gunnar Antoni(Uppsala University), Per Hellman(Uppsala University Hospital), Franklin I. Aigbirhio(University of Cambridge), Mark Gurnell(University of Cambridge), Mark Lubberink(Uppsala University), Lleah O’Sullivan(Uppsala University), Morris J. Brown(St Bartholomew's Hospital), Anders Wall(Uppsala University), Sara Roslin(Uppsala University), Tobias Åkerström(Uppsala University), Anders Sundin
European Journal of Nuclear Medicine and Molecular Imaging
September 8, 2022
10.1007/s00259-022-05957-9
Cited by 31

Related Papers

Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Traumatic brain injury: progress and challenges in prevention, clinical care, and research
|The Lancet Neurology|2022|1.3k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951